Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (51-60 of 179) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Haematologica|August 24, 2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedAmr R Ibrahim, Richard E Clark, Tessa L Holyoake, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
International Review of Psychiatry (Abingdon, England)|May 18, 2022
The role of global vulnerability for mental and substance use disordersMaria Olivia Pozzolo Pedro, Mateus Nobuo Sakata Angelo, Matheus Cheibub David Marin, et al.
Lancet (London, England)|August 29, 2003
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfaDavid Marin, Sarah Marktel, Richard Szydlo, et al.
Haematologica|February 25, 2010
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axisFabrizio Vianello, Federica Villanova, Veronica Tisato, et al.
American Journal of Hematology|February 18, 2011
Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesGareth Gerrard, Katherine Mudge, Rebecca Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisHugues de Lavallade, Jane F Apperley, Jamshid S Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progressionJamshid S Khorashad, Hugues de Lavallade, Jane F Apperley, et al.
Blood Advances|January 11, 2023
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor typeRohtesh S Mehta, David Marin, Amin Alousi, et al.
Pageof 18

Showing results (51-60 of 179) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Haematologica|August 24, 2011
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failedAmr R Ibrahim, Richard E Clark, Tessa L Holyoake, et al.
Blood|December 17, 2011
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patientsDragana Milojkovic, Jane F Apperley, Gareth Gerrard, et al.
International Review of Psychiatry (Abingdon, England)|May 18, 2022
The role of global vulnerability for mental and substance use disordersMaria Olivia Pozzolo Pedro, Mateus Nobuo Sakata Angelo, Matheus Cheibub David Marin, et al.
Lancet (London, England)|August 29, 2003
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfaDavid Marin, Sarah Marktel, Richard Szydlo, et al.
Haematologica|February 25, 2010
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axisFabrizio Vianello, Federica Villanova, Veronica Tisato, et al.
American Journal of Hematology|February 18, 2011
Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignanciesGareth Gerrard, Katherine Mudge, Rebecca Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisHugues de Lavallade, Jane F Apperley, Jamshid S Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progressionJamshid S Khorashad, Hugues de Lavallade, Jane F Apperley, et al.
Blood Advances|January 11, 2023
Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor typeRohtesh S Mehta, David Marin, Amin Alousi, et al.
Pageof 18